Recompensation has gained increasing attention in the field of cirrhosis, particularly in
chronic liver disease with a definite aetiology. The current global prevalence of obesity and …

Non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH) has become the leading
cause of liver disease worldwide. NASH, an advanced form of NAFL, can be progressive …

The exclusion of other chronic liver diseases including “excess” alcohol intake has until now
been necessary to establish a diagnosis of metabolic dysfunction-associated fatty liver …

Background and aims Metabolic associated fatty liver disease (MAFLD) is a novel concept
proposed in 2020, the utility of which has not been tested and validated in real world. We …

Caloric excess and sedentary lifestyle have led to a global epidemic of obesity and
metabolic syndrome. The hepatic consequence of metabolic syndrome and obesity …

Fatty liver associated with metabolic dysfunction is common, affects a quarter of the
population, and has no approved drug therapy. Although pharmacotherapies are in …

Alcohol use and metabolic syndrome are highly prevalent in the population and frequently
co-exist. Both are implicated in a large range of health problems, including chronic liver …

Background & aims Metabolic dysfunction–associated fatty liver disease (MAFLD)
establishes new criteria for diagnosing fatty liver disease independent of alcohol intake and …

Nonalcoholic fatty liver disease (NAFLD) is a global public health concern. Its natural history,
the development of nonalcoholic steatohepatitis (NASH) and fibrosis, is highly variable …

Alcoholic liver disease (ALD) is the most prevalent type of chronic liver disease worldwide.
ALD can progress from alcoholic fatty liver (AFL) to alcoholic steatohepatitis (ASH), which is …